Clal Biotechnology Industries - Full-year financial results
Clal Biotechnology Industries’ (CBI’s) portfolio of investments continues to advance on multiple fronts. MediWound recently reported positive top-line data from its US Phase III study of NexoBrid, and if all goes according to plan, the company expects to file a BLA application with the FDA in H219. Additionally, according to Gamida Cell, its cash balance should provide a runway through March 2020, which is roughly in line with company expectations for delivering top-line NiCord Phase III data.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.